Journal articleJAMA Oncol2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.
- Journal
- JAMA Oncol
- Published
- 1 August 2024
- Citations
- 37
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsCombination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer NCT02047474↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.
Grants 3
- Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer K99CA226342↗
- Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer R00CA226342↗
- Understanding and targeting mutant splicing factors in pancreatic cancer R01CA274355↗